CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

to the Loan and Security Agreement, dated as of June 30, 2023, by and among the COMPASS Pathways plc, and its subsidiaries, the lenders party thereto and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent

EXECUTION VERSION SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is dated as of July 30, 2025 and is entered into by and among COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales (“Company”), COMPASS Pathfinder Holdings Limited, a private limited company incorporated under the laws of England and Wales (“COMPASS Pathfinder Holdings”), COMPASS Pathfinder Limited, a private limited company incorporated and registered in England and Wales (“COMPASS Pathfinder Limited”), COMPASS Pathways, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights •Positive primary endpoint achieved in first COMP360 Phase 3 trial with high statistical significance, clinically meaningful reduction in depression at 6 weeks, and no unexpected safety findings •Second ongoing pivotal Phase 3 trial continues to enroll well, with 26-week data expected in the second half of 2026 •Compass exploring options for potential accelerated COMP360 filing for TRD •Cash position of $221.

License Agreement and Addendum between Fora Space Limited and COMPASS Pathfinder Limited dated June 6, 2025.

agreementforaspacelimit ADDENDUM 1. ADDENDUM This Addendum amends and supplements the terms of the Fora Office Usage and Service Agreement (Contract No. 00043764). 2. TERMS DEFINED IN THE AGREEMENT In this Addendum, expressions defined in the Agreement and used in this Addendum have the meaning set out in the Agreement, unless otherwise specified in this Addendum. 3. VARIATION 3.1 With effect from

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

Compass Pathways Appoints Justin Gover to Board of Directors

Exhibit 99.1   Compass Pathways Appoints Justin Gover to Board of Directors LONDON & NEW YORK, July 29, 2025   Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Justin Gover to its Board of Directors, effective immediately. Mr. Gover brings more than 25 years of lea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2025 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2025 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

COMPASS PATHWAYS PLC Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (expressed in U.S. Dollars, unless otherwise stated)

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights Highlights: •6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June •Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 •Cash position of $260.

Master Research Collaboration Agreement by and among COMPASS Pathfinder Limited, King’s College London and South London and Maudsley NHS Foundation Trust, dated March 22, 2022

Exhibit 10.4 Certain confidential information in this document has been omitted from this exhibit and replaced with “[***]” because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. AMENDMENT No. 1 to MASTER RESEARCH COLLABORATION AGREEMENT This Amendment No. 1 (the “Amendment”), effective as of 30 April 2025 (the “Amendment Effective Date”), is m

between Compass Pathways

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) is dated May 7, 2025 and amends that certain Employment Agreement entered into as of December 6, 2023 (the “Employment Agreement”), by and COMPASS Pathways, Inc. (the “Company”), a Delaware corporation with a principal place of business at 44 West 37th Street, 7th Floor New York, NY 10018, and Teri Loxam, residing at x

$150,000,000 American Depositary Shares representing Ordinary Shares

 Filed pursuant to Rule 424(b)(5)  Registration Statement No. 333-285297 PROSPECTUS $150,000,000 American Depositary Shares representing Ordinary Shares We are party to a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, dated February 27, 2025, relating to the sale of our American Depositary Shares, or ADSs, offered by this prospectus. In accordance with the term

Amended and Restated Employment Agreement dated

guyaragreement 4135-1945-7548, v. 3 STRICTLY PRIVATE AND CONFIDENTIAL Dated 26 July 2021 (as amended and restated on 7 May 2025) COMPASS PATHFINDER LIMITED and GUY GOODWIN SERVICE AGREEMENT 1 4135-1945-7548, v. 3 THIS AGREEMENT is entered into between the parties on 26 July 2021 and is amended and restated as of 7 May 2025. PARTIES (1) COMPASS PATHFINDER LIMITED a company incorporated and register

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 08, 2025 COMPASS PATHWAYS PLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 08, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

between Compass Pathfinder L

STRICTLY PRIVATE AND CONFIDENTIAL Dated 15 April 2024 (as amended and restated on 7 May 2025) COMPASS PATHFINDER LIMITED and Kabir Nath SERVICE AGREEMENT 4135-1945-7548, v.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

May 5, 2025

May 5, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Compass Pathways plc Acceleration Request for Registration Statement on Form S-3 (File No. 333-285297) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Compass Pathways plc (the “Compa

COMPASS Pathways plc 2024 Annual Report

COMPASS Pathways plc 2024 Annual Report Registered number: 12696098 COMPASS PATHWAYS PLC ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 INTRODUCTION AND CONTENTS Compass Pathways plc (“the Company”, or “the Parent Company”) is a public company limited by shares and incorporated under the laws of the United Kingdom and is listed on the Nasdaq Global Select Market.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Letter from PwC UK to the Securities and Exchange Commission, dated April 16, 2025.

Exhibit 16.1 [PricewaterhouseCoopers LLP letterhead] April 16, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Compass Pathways plc (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Compass Pathways plc dated April 16, 2025. We agree

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2025 COMPASS PATHWAYS P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Settlement Agreement with Matthew Owens

Exhibit 10.22 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Dated 19 December 2024 COMPASS PATHFINDER LIMITED (1) and MATTHEW OWENS (2) SETTLEMENT AGREEMENT BETWEEN (1)Compass Pathfind

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 27, 2025 COMPASS PATHWAY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 27, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ⊠ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc (Exa

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

First Amendment dated October 30, 2024 to the Loan and Security Agreement, dated as of June 30, 2023, by and among the COMPASS Pathways plc, and its subsidiaries, the lenders party thereto and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent

hercules-compassxfirsta Execution Version sf-6170959 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of October 30, 2024 and is entered into by and among COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales (“Company”), COMPASS Pathfinder Holdings Limited, a private limited company incorporated under the laws of England and Wales (“COMPASS Pathfinder Holdings”), COMPASS Pathfinder Limited, a private limited company incorporated and registered in England and Wales (“COMPASS Pathfinder Limited”), COMPASS Pathways, Inc.

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights Highlights: •Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025 •Phase 3 COMP006 in TRD is on track for 26-week data in second half of 2026 •Cash position of $165.

ompass Pathways plc I

Exhibit 19.1 COMPASS PATHWAYS PLC INSIDER TRADING POLICY This memorandum sets forth the policy of COMPASS Pathways plc and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the ap

, 2025 by and between the Registrant and TD Securities (USA) LLC.

Exhibit 1.2 COMPASS PATHWAYS PLC AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES SALES AGREEMENT February 27, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales with registered number 12696098 (the “Company”), confirms its agreement (this “Agreement”)

Fee Filing Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value £0.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity(2) Ordinary Shares, nominal value £0.

Opinion of Goodwin Procter (UK) LLP relating to the Sales Agreement Prospectus

Exhibit 5.3 Goodwin Procter (UK) LLP 10-15 Newgate St London EC1A 7AZ goodwinlaw.com +44 (0) 20 7447 4200 27 February 2025 COMPASS Pathways plc 3rd Floor, 1 Ashley Road Altrincham, Cheshire United Kingdom, WA14 2DT Ladies and Gentlemen: COMPASS Pathways plc – Prospectus – Exhibit 5.3 We have acted as English law advisers to COMPASS Pathways plc, a public limited company incorporated in England and

JOINT FILING AGREEMENT

EX-99.1 2 tm255641d1ex-1.htm EXHIBIT 1 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the American Depositary Shares, each representing one ordinary share, par value of GBP 0.008 per share,

Form of ADS Warrant

FORM OF WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES COMPASS PATHWAYS PLC Warrant No.

Underwriting Agreement between the Company, TD Securities (USA) LLC, Cantor Fitzgerald & Co., Stifel, Nicolaus & Company, Incorporated and RBC Capital Markets, LLC, dated as of January 10, 2025

COMPASS Pathways plc 24,014,728 American Depositary Shares Representing 24,014,728 Ordinary Shares Pre-Funded Warrants to Purchase up to 11,044,720 American Depositary Shares Representing Ordinary Shares Warrants to Purchase up to 35,059,448 American Depositary Shares Representing Ordinary Shares UNDERWRITING AGREEMENT January 10, 2025 TD SECURITIES (USA) LLC CANTOR FITZGERALD & CO.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2025 COMPASS PATHWAYS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2025 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (

24,014,728 American Depositary Shares Representing 24,014,728 Ordinary Shares Pre-Funded Warrants to Purchase up to 11,044,720 American Depositary Shares Representing 11,044,720 Ordinary Shares Warrants to Purchase up to 35,059,448 American Depositar

Filed pursuant to Rule 424(b)(5) Registration No. 333-282522 PROSPECTUS SUPPLEMENT (To Prospectus dated October 17, 2024) 24,014,728 American Depositary Shares Representing 24,014,728 Ordinary Shares Pre-Funded Warrants to Purchase up to 11,044,720 American Depositary Shares Representing 11,044,720 Ordinary Shares Warrants to Purchase up to 35,059,448 American Depositary Shares Representing 35,059

Compass Pathways Announces Pricing of Underwritten Offering

Exhibit 99.1 Compass Pathways Announces Pricing of Underwritten Offering London and New York, January 10, 2025 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain ins

Form of Pre-funded Warrant

FORM OF PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES COMPASS PATHWAYS PLC Warrant No.

CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2427061d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* COMPASS Pathways plc (Name of Issuer) American Depositary Shares, each representing one ordinary

CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm2427604d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share** (Title of Class of Securities) 20451W101*** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 COMPASS PATHWAYS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates •Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 •COMP006 data will now be announced

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates •Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 •COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 •Strategic reorganization to focus all efforts on COMP360 program resulting in reduction

$93,512,230 American Depositary Shares representing Ordinary Shares

 Filed pursuant to Rule 424(b)(5)  Registration Statement No. 333-282522 PROSPECTUS $93,512,230 American Depositary Shares representing Ordinary Shares We are party to a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, dated October 8, 2021, relating to the sale of our American Depositary Shares, or ADSs, offered by this prospectus. In accordance with the terms o

October 15, 2024

October 15, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

As filed with the Securities and Exchange Commission on October 7, 2024

As filed with the Securities and Exchange Commission on October 7, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity(2) Ordinary Shares, nominal value £0.

Opinion of Goodwin Procter (UK) LLP relating to the Sales Agreement Prospectus

Exhibit 5.3 Goodwin Procter (UK) LLP 10-15 Newgate St London EC1A 7AZ goodwinlaw.com +44 (0) 20 7447 4200 7 October 2024 COMPASS Pathways plc 3rd Floor, 1 Ashley Road Altrincham, Cheshire United Kingdom, WA14 2DT Ladies and Gentlemen: COMPASS Pathways plc – Prospectus – Exhibit 5.3 We have acted as English law advisers to COMPASS Pathways plc, a public limited company incorporated in England and W

CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) / ATAI Life Sciences B.V. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Wallstraße 16, 10179 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Number of Person A

Compass Pathways announces second quarter 2024 financial results and business highlights •Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment- resistant depression expected in fourth quarter 2024 •Gino Santini to join Board of Dire

Compass Pathways announces second quarter 2024 financial results and business highlights •Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment- resistant depression expected in fourth quarter 2024 •Gino Santini to join Board of Directors as Chairman •Lori Englebert named new Chief Commercial Officer •Cash position of $228.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2024 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

Compass Pathways plc

Exhibit (b)(v) Compass Pathways plc August 18, 2023 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Attention: Ryan Everett Re: Second Amended and Restated Restricted ADS Letter Agreement - Affiliate and Restricted Securities Series Letter Agreement Ladies and Gentlemen: Reference is hereby made to (i) the Deposit Agreement, dated as of September 22, 2020 (the “Deposi

DEPOSIT AGREEMENT by and among COMPASS PATHWAYS PLC CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of September 22, 2020 TABLE OF CONTENTS

Exhibit (a) DEPOSIT AGREEMENT by and among COMPASS PATHWAYS PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of September 22, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 1 Sectio

COMPASS PATHWAYS PLC

Exhibit (b)(iii) COMPASS PATHWAYS PLC October 12, 2022 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Attn: Ryan Everett Program ADSs (CUSIP No.: 20451W101) Ladies and Gentlemen: Reference is hereby made to the Deposit Agreement, dated as of September 22, 2020, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Compass Pathways plc,

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS Compass PATHWAYS PLC (Exact name of issuer of deposited secu

As filed with the Securities and Exchange Commission on May 15, 2024 Registration No.

Compass Pathways plc

Exhibit (b)(vii) Compass Pathways plc August 18, 2023 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Attention: Ryan Everett Re: Warrant Exercise Series Letter Agreement Ladies and Gentlemen: Reference is hereby made to (i) the Deposit Agreement, dated as of September 22, 2020 (the “Deposit Agreement”), by and among Compass Pathways plc, a public limited company inco

Compass Pathways plc

Exhibit (b)(iv) Compass Pathways plc August 18, 2023 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Attention: Ryan Everett Re: Restricted ADSs (CUSIP No.: 20451W994) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of September 22, 2020, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Compass Pathways p

Exhibit (d)

Exhibit (d) May 15, 2024 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the United

COMPASS Pathways plc

Exhibit (b)(ii) COMPASS Pathways plc As of December 28, 2021 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: Restricted ADSs (CUSIP No.: 20451W994) Ladies and Gentlemen: Reference is made to that certain (i) Deposit Agreement, dated as of September 22, 2020, as amended and supplemented from time to time (the “Deposit Agreement”), by and among COMPASS Pathways plc,

COMPASS Pathways plc

Exhibit (b)(i) COMPASS Pathways plc As of September 24, 2020 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: Restricted ADSs (CUSIP No.: 20451W994) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of September 22, 2020, as amended and supplemented from time to time (the “Deposit Agreement”), by and among COMPASS Pathways plc, a public lim

Compass Pathways plc

Exhibit (b)(vi) Compass Pathways plc August 18, 2023 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Attention: Ryan Everett Re: PIPE Securities Series Letter Agreement Ladies and Gentlemen: Reference is hereby made to (i) the Deposit Agreement, dated as of September 22, 2020 (the “Deposit Agreement”), by and among Compass Pathways plc, a public limited company incorp

Rule 466 Certification

Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (i) That it previously had filed a registration statement on Form F-6 (Registration No. 333-248514), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement except for the number of s

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 09, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 08, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

ment Agreement dated

ukemploymentagreementkab 4135-1945-7548, v. 3 STRICTLY PRIVATE AND CONFIDENTIAL Dated 15 April 2024 COMPASS PATHFINDER LIMITED and Kabir Nath SERVICE AGREEMENT 1 4135-1945-7548, v. 3 THIS AGREEMENT is entered into between the parties with retroactive effect to 6 April 2024. PARTIES (1) COMPASS PATHFINDER LIMITED a company incorporated and registered in England and Wales with company number 1022925

hew Owens, as amended effective

exhibit101mattemployment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 08, 2024 COMPASS PATHWAYS PLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 08, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights •COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line d

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights •COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 •Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) •Michael Gold to join Compass as Head of R&D •Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care •Cash position of $262.

CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G 1 CMPSSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 COMPASS PATHWAYS PLC (Name of Issuer) ORDINARY SHARES, NOMINAL VALUE £0.008 PER SHARE (Title of Class of Securities) 20451W101** (CUSIP Number) APRIL 2, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2024 COMPASS PATHWAYS P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair London – March 28, 2024 Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2024.

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights London, UK – February 29, 2024 Highlights: •COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025 •Teri Loxam to assume Chief Financial Officer role on March 1, 2024 •Cash position of $220.

Compass Pathways plc Compensation Recovery Policy

COMPASS PATHWAYS PLC COMPENSATION RECOVERY POLICY Adopted as of November 1, 2023 COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below.

Employment Agreement dated May 7, 2020 by and between Compass Pathways and Mary-Rose Hughes, as amended

exhibit1024 COMPASS Pathways Limited is a UK private limited (by shares) company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom Private & confidential SUBJECT TO CONTRACT SUBJECT TO REFERENCES Mary-Rose Hughes By E-mail 7th May 2020 Dear Mary-Rose Offer of employment I am pleased to write to you with an offer of employment with COMPASS Pathways Limited, a company incorporated in England and Wales (registered number 10229259) whose registered office is at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom (the 'Company').

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ⊠ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 29, 2024 COMPASS PATHWAY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 29, 2024 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

Amendment to Employment Agreement dated August 1, 2023 by and between Kabir Nath and Compass Pathways, Inc. dated August 1, 2023

[COMPASS PATHWAYS LETTERHEAD] Kabir Nath 115 North Union Street Lambertville, NJ 08530 21 December 2023 STRICTLY PRIVATE & CONFIDENTIAL Dear Kabir, Changes to your employment agreement This letter confirms the following changes to your employment agreement with Compass Pathways, Inc.

GB:CMPS / Compass Pathways Plc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm245955d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share** (Title of Class of Securities) 20451W101*** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this st

GB:CMPS / Compass Pathways Plc / Goldsmith George Jay - SC 13G/A Passive Investment

SC 13G/A 1 compass-schedule13gamendme.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share (Title of Class of Securities) 20451W101 (1) (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of

As filed with the Securities and Exchange Commission on January 5, 2024

As filed with the Securities and Exchange Commission on January 5, 2024 Registration No.

Fee Filing Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value £0.

GB:CMPS / Compass Pathways Plc / CITADEL ADVISORS LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) American Depositary Shares, each representing one ordinary share, par value £0.008 per share (the “Sha

GB:CMPS / Compass Pathways Plc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share** (Title of Class of Securities) 20451W101*** (CUSIP Number) December 20, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to desig

Joint Filing Agreement

EX-99.1 2 tm241562d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares, nominal value £0.008 per share, of COMPASS Pathways plc, and furth

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 19

Compass Pathways appoints Teri Loxam as Chief Financial Officer

Exhibit 99.1 Compass Pathways appoints Teri Loxam as Chief Financial Officer London, UK – December 7, 2023 Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 COMPASS PATHWAYS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-395

Employment Agreement dated December 6, 2023, by and between Compass Pathways and Teri Loxam.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of 6 December 2023 (the “Effective Date”), is entered into by and between COMPASS Pathways, Inc. (the “Company”), a Delaware corporation with a principal place of business at 44 West 37th Street, 7th Floor New York, NY 10018, and Teri Loxam, residing at 3 Rossiter Circle, New Hope, PA, 18938 (the “Employee” or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 02, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

Lease Agreement between Azul NYC LLC and COMPASS Pathways, Inc. dated September 28, 2023.

AGREEMENT OF LEASE BETWEEN AZUL NYC LLC, AS LANDLORD, AND COMPASS PATHWAYS, INC., AS TENANT. PREMISES: Entire Seventh (7th) Floor 44 West 37th Street New York, New York TABLE OF CONTENTS Article Page 1.Basic Lease Terms 1 2.Use and Occupancy 3 3.Tenant's Alterations 3 4.Repairs 5 5.Window Cleaning 6 6.Requirements of Law; Floor Load 6 7.Subordination 7 8.Rules and Regulations 9 9.Insurance 9 10.De

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights London, UK – November 2, 2023 Highlights: •COMP360 Phase 3 pivotal program ongoing with expanding European clinical sites •Secured up to $285 million private placement financing with $125 million upfront •Cash position at September 30, 2023 of $248.

dated October 24, 2023

October 24, 2023 Mr. Michael Falvey 5 Pine Ridge Drive Mattapoisett, MA 02739 United States Re: Separation Agreement and Release Dear Mike: This letter agreement (this “Agreement”) sets forth the terms and conditions of your mutually agreed separation from employment with COMPASS Pathways, Inc. (“COMPASS” or the “Company”). Your separation from employment with the Company is effective as of Novemb

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-395

COMPASS Pathways announces CFO transition

Exhibit 99.1 COMPASS Pathways announces CFO transition London, UK – October 26, 2023 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities. Ma

40,089,163 American Depositary Shares Representing 40,089,163 Ordinary Shares Offered by the Selling Securityholders

Filed pursuant to Rule 424(b)(3) Registration No. 333-274436 PROSPECTUS 40,089,163 American Depositary Shares Representing 40,089,163 Ordinary Shares Offered by the Selling Securityholders This prospectus relates to the proposed resale or other disposition by the selling securityholders identified herein of (i) 32,153,500 ADSs including (a) up to 16,076,750 American Depositary Shares, or ADSs, pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 COMPASS PATHWA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-3

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Exhibit 99.1 COMPASS Pathways appoints Daphne Karydas to its Board of Directors London, UK, September 18, 2023 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is Presid

September 14, 2023

September 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acceleration Request for COMPASS Pathways plc Registration Statement on Form S-3 (File No. 333-274436) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, COMPASS Pathways plc hereby requests that the effective date f

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to Be Paid Equity American Depositary Shares, each representing one ordinary share, nominal value £0.

As filed with the Securities and Exchange Commission on September 8, 2023

As filed with the Securities and Exchange Commission on September 8, 2023 Registration No.

GB:CMPS / Compass Pathways Plc / TCG Crossover GP I, LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share (Title of Class of Securities) 20451W101 ** (CUSIP Number) August 18, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to de

JOINT FILING AGREEMENT

Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.

GB:CMPS / Compass Pathways Plc / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 ea184249-13gvivocompass.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) Ordinary Shares, par value £0.008 per share, represented by American Depositary Shares (Title of Class of Securities) 20451W101** (CUSIP Number) August 18, 2023 (Date

Joint Filing Statement

EX-99.1 2 ea184249ex99-1compass.htm JOINT FILING STATEMENT Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing

Securities Purchase Agreement, dated August 16, 2023, by and among the Company and the Purchasers.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2023 (the “Effective Date”), by and among COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

Exhibit 99.1 COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors · Transaction led by healthcare specialist investors, TCGX and Aisling Capital · $125 million financing upfront with up to an additional $160 million tied to exercise of warrants · Net proceeds from financing expected to extend cash runway into late 2025 London, UK – August

Form of PIPE Investor Warrant

Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE OFFER AND SALE OF SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD,

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-3952

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 03, 2023 COMPASS PATHWAYS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 03, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights London, UK – August 3, 2023 Highlights: •COMP360 Phase 3 pivotal program ongoing and on track •CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association •Cash position at June 30, 2023 of $148.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital London, UK – July 5, 2023 COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc.

Form of Lender Warrant

Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY U.S. STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COM

Loan and Security Agreement, dated as of June 30, 2023, by and among the COMPASS Pathways plc, and is entered into by and among COMPASS Pathways plc and its subsidiaries, the lenders party thereto and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent.

Exhibit 10.1 Certain confidential information in this document has been omitted from this exhibit and replaced with “[***]” because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is dated as of June 30, 2023, and is entered into by and among COMPASS Pathways plc, a public limited comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 COMPASS PATHWAYS PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2023 COMPASS PATHWAYS PLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522 N

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer She will remain a member of the COMPASS Pathways Board of Directors

Exhibit 99.1 COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer She will remain a member of the COMPASS Pathways Board of Directors London, May 31, 2023 – COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

License Agreement between Fora Space Limited and COMPASS Pathfinder Limited dated April 4, 2023.

foraresidentagreement Fora Space Limited (“Fora”) Licence Agreement Contract number: 007211 Licensee details Licensee Name Compass Pathfinder Limited Telephone +16469053974 Principal contact name Kabir Nath Email kabir.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 COMPASS PATHWAYS PLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights London, UK – May 11, 2023 Highlights: •COMP360 Phase 3 pivotal program underway, patients have been treated in both trials •CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association •Cash position at 31 March 2023 of $117.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (C

COMPASS Pathways plc 2022 Annual Report Registered number: 12696098 COMPASS PATHWAYS PLC ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 1 ANNUAL REPORT AND FINANCIAL STATEMENTS INTRODUCTION AND CONTENTS COMPASS Pathways pl

compassfy2022ars19april2 COMPASS Pathways plc 2022 Annual Report Registered number: 12696098 COMPASS PATHWAYS PLC ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 1 ANNUAL REPORT AND FINANCIAL STATEMENTS INTRODUCTION AND CONTENTS COMPASS Pathways plc (“the Company”, or “the Parent Company”) is a public limited company incorporated under the laws of England and Wales and is listed on the Nasdaq Global Select Market.

Transforming Mental Health Care April 19, 2023 2 | © COMPASS Pathways plc 2023 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform

exhibit991compassinvesto Transforming Mental Health Care April 19, 2023 2 | © COMPASS Pathways plc 2023 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Restricted share unit award agreement for company employees under the COMPASS Pathways plc 2020 Share Option and Incentive Plan

RESTRICTED SHARE UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE COMPASS PATHWAYS PLC 2020 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No.

Description of Securities

Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of COMPASS Pathways plc (the “Company”) American Depositary Shares (“ADSs”), each representing one ordinary share, nominal value £0.008 per share. This description also summarizes relevant provisions of English law.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 28, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

WeWork Membership Agreement dated August 22, 2022 by and between COMPASS Pathways Inc and 130 Madison Avenue Tenant LLC

weworkmembershipagreeme WEWORK MEMBERSHIP AGREEMENT This WeWork membership agreement (the “Agreement”), effective as of the date the Agreement is fully executed below (“Effective Date”), is entered by and between Member Company and WeWork.

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights London, UK – February 28, 2023 Highlights: •Phase 3 pivotal program underway - important updates announced •Phase 3 long term follow up defined •Cash position at 31 December 2022 of $143.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ⊠ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc (Exa

GB:CMPS / Compass Pathways Plc / COMPASS Pathways plc - SC 13G/A Passive Investment

SC 13G/A 1 compass-schedule13gamendme.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value £0.008 per share (Title of Class of Securities) 20451W101 (1) (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of

Fee Filing Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value £0.

As filed with the Securities and Exchange Commission on January 20, 2023

S-8 1 compass-sx82023evergreensh.htm S-8 As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 COMPASS PATHWAYS PLC (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other ju

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2023 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (

Transforming Mental Health Care JANUARY 2023 2 | © COMPASS Pathways plc 2023 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform A

Transforming Mental Health Care JANUARY 2023 2 | ? COMPASS Pathways plc 2023 Cautionary Note Regarding Forward-Looking Statements This presentation includes ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 03, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights London, UK – November 3, 2022 Highlights: •Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiated •Phase 2b trial data published in The New England Journal of Medicine •Cash position at 30 September 2022 of $173.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39522 COMPASS Pathways plc

Inducement Non-Qualified Share Option Agreement, by and between the Registrant and Mr. Nath, dated August 1, 2022.

Exhibit 4.4 COMPASS PATHWAYS PLC INDUCEMENT NON-QUALIFIED SHARE OPTION AGREEMENT Name of Optionee: Kabir Nath No. of Option Shares: 600,000 Option Exercise Price per Share: $14.94 Grant Date: August 1, 2022 Vesting Commencement Date: August 1, 2022 Expiration Date: July 31, 2032 COMPASS Pathways plc (the ?Company?) hereby grants to the Optionee named above an option (the ?Share Option?) to purchas

Fee Filing Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value ?0.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights London, UK ? 4 August 2022 Highlights: ?Kabir Nath appointed as Chief Executive Officer ?Phase III program submitted to FDA and under review ?COMP360 phase II study in anorexia nervosa launched ?Cash position at 30 June 2022 of $207.

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

Form of Inducement Award Non-Qualified Share Option Agreement.

Exhibit 10.3 COMPASS PATHWAYS PLC INDUCEMENT NON-QUALIFIED SHARE OPTION AGREEMENT Name of Optionee: No. of Option Shares: Option Exercise Price per Share: [FMV on Grant Date] Grant Date: Vesting Commencement Date: Expiration Date: COMPASS Pathways plc (the ?Company?) hereby grants to the Optionee named above an option (the ?Share Option?) to purchase on or prior to the Expiration Date specified ab

Employment Agreement dated August 1, 2022 by and between COMPASS Pathways plc and Kabir Nath.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is effective as of 1 August 2022 (the ?Effective Date?), and is entered into by and between the Company (hereinafter defined), and Executive (hereinafter defined) (collectively with the Company, the ?Parties?; each of the Parties referred to individually as a ?Party?). WHEREAS, the Company desires to employ Executive in

COMPASS Pathways Appoints Kabir Nath as Chief Executive Officer Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsm

Exhibit 99.1 COMPASS Pathways Appoints Kabir Nath as Chief Executive Officer Kabir Nath will build upon COMPASS? success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains COMPASS? Chairman London, UK ? July 19, 2022 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company de

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Co

Amendment to Employment Agreement dated September 14, 2020 by and between COMPASS Pathways plc and George Goldsmith.

Exhibit 10.2 [COMPASS PATHWAYS LETTERHEAD] George Goldsmith 10 Connaught Place Flat 2 London W2 2ET 19 July 2022 STRICTLY PRIVATE & CONFIDENTIAL Dear George, Changes to your service agreement This letter confirms the following changes to your service agreement with COMPASS Pathfinder Limited dated 14 September 2020 (Service Agreement), will take effect from 1 August 2022: 1.Clause 2.1 of the Servi

As filed with the Securities and Exchange Commission on July 1, 2022

S-8 1 compass-sx82022evergreensh.htm S-8 As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 COMPASS PATHWAYS PLC (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisd

Fee Filing Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value ?0.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

Master Research Collaboration Agreement by and among COMPASS Pathfinder Limited, King’s College London and South London and Maudsley NHS Foundation Trust, dated March 22, 2022

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?.

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights London, UK ? 10 May 2022 Highlights: ?End of phase II meeting held with FDA ?Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP ?Finalising phase III in TRD program design to be ready for second half of 2022 ?Pioneering collaboration with King?s College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK ?Cash position at 31 March 2022 of $243.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-39522 Not applicable (State or other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39522 COMPASS Pathways plc (Exact name of registrant as spec

$150,000,000 American Depositary Shares representing Ordinary Shares

?Filed pursuant to Rule 424(b)(5) ?Registration Statement No. 333-260145 PROSPECTUS SUPPLEMENT (To Prospectus dated May 3, 2022) $150,000,000 American Depositary Shares representing Ordinary Shares We have previously entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, dated October 8, 2021, relating to the sale of our American Depositary Shares, or ADSs,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 cmps-schedule14adefproxyst.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39522

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK Pioneering collaboration with King?s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 - COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (?the Centre?) to accelerate psychedelic research and develop new models of care for mental health in the UK.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-39

As filed with the Securities and Exchange Commission on February 24, 2022.

POS AM 1 cmps-posamsx3.htm POS AM As filed with the Securities and Exchange Commission on February 24, 2022. Registration Statement No. 333-260145 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-3 Registration Statement UNDER THE SECURITIES ACT OF 1933 COMPASS Pathways plc (Exact name of registrant as specified in its charter) Englan

Services Agreement by and between BioInnovation Labs LLC and COMPASS Pathways Inc dated January 31, 2022

Services Agreement Page 1 of 9 Name of Licensee organization?s legal entity: Mailing Address Email Address Licensee federal tax ID# (if left blank, agreement becomes a personal obligation of signer) Signature: Name of authorized signer: Title: BioInnovation Labs LLC Signature: Officer?s name: Title: People Coordinator 6th F New York, NY, 10014 180 Varick Street 833496958 COMPASS Pathways Inc mark.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) COMPASS Pathways plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(3) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity(1) Ordinary Shares, nominal value ?0.

Service Agreement by and between Movassate Family Trust and COMPASS Pathways Inc dated August 3, 2021

LEASE for 164 Townsend Street, #3 between Movassate Family Trust, Landlord and Compass Pathways, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39522 COMPASS Pathways plc (Exact name of registrant as specified

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights London, UK ? 24 February 2022 Highlights: ?Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support ?Positive results f

Employment Agreement with Matthew Owens

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?.

As filed with the Securities and Exchange Commission on February 24, 2022.

As filed with the Securities and Exchange Commission on February 24, 2022. Registration Statement No. 333?260145 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post?Effective Amendment No. 1 to Form F?3 on Form S?3 Registration Statement UNDER THE SECURITIES ACT OF 1933 COMPASS Pathways plc (Exact name of registrant as specified in its charter) England and Wales Not Applic

GB:CMPS / Compass Pathways Plc / THIEL PETER - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 COMPASS Pathways plc (Name of Issuer) Ordinary shares, nominal value ?0.008 per share** (Title of Class of Securities) 20451W101** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to design

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2022 COMPASS PATHWAYS PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales (State or Other Jurisdiction of Incorporation) England and Wales 001-395

Form of Restricted Share Unit Award Agreement for Company Employees under the 2020 Share Option and Incentive Plan.

RESTRICTED SHARE UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE COMPASS PATHWAYS PLC 2020 SHARE OPTION AND INCENTIVE PLAN Name of Grantee: No.

Form of Non-Qualified Share Option Agreement for Company Employees under the 2020 Share Option and Incentive Plan.

NON-QUALIFIED SHARE OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE COMPASS PATHWAYS PLC 2020 SHARE OPTION AND INCENTIVE PLAN Name of Optionee: No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 33 Broadwick Street London W1F 0DQ United Kingdom Tel: +1 (646) 905-3974 (Ad

COMPASS Pathways announces changes in Executive Team Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role

COMPASS Pathways announces changes in Executive Team Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK ? 16 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Matthew Owens as General Counsel and Chief Legal Officer.

Employment Agreement with Michael Falvey

EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of November 15, 2021 (the ?Effective Date?), is entered into by and between COMPASS Pathways, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 33 Broadwick Street London W1F 0DQ United Kingdom Tel: +1 (646) 905-3974 (Ad

Michael Falvey to join COMPASS Pathways as Chief Financial Officer

Michael Falvey to join COMPASS Pathways as Chief Financial Officer London, UK ? 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year.

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression ?Positive topline results validated by additional analyses ?Patient improvements beyond reduction of depression symptoms ?Further insights into timing and circumstance of adverse events demonstrate COMP360 psilocybin therapy was ge

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

GB:CMPS / Compass Pathways Plc / Logos Global Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Compass Pathways plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 20451W1011 (CUSIP Number) November 22, 20212 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

GB:CMPS / Compass Pathways Plc / ATAI Life Sciences B.V. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Krausenstraße 9-10, 10117 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Numb

GB:CMPS / Compass Pathways Plc / ATAI Life Sciences B.V. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Krausenstra?e 9-10, 10117 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Number of Per

COMPASS Pathways granted fifth US patent for crystalline psilocybin

COMPASS Pathways granted fifth US patent for crystalline psilocybin London, UK ? 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

The General Counsel and Chief Legal Officer’s Settlement Agreement dated September 29, 2021 with the Company

ACTIVE/111655028.5 11 TRANSITION AGREEMENT This Transition Agreement (?Agreement?) is made between Compass Pathways, Inc., a Delaware corporation (the ?Company?) and Nathan Poulsen (the ?Executive?). The Company together with the Executive shall be referred to as the ?Parties?. Terms with initial capitalization not otherwise defined shall have the meanings ascribed to such terms in the Employment

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 London, UK ? 9 November 2021 Highlights: ?Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25 mg dose of COMP360 psilocybin with psychological support ?Launch of phase II study of

Presentation dated

Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2

The President, Chief Business Officer and Co-founder’s Part-Time Agreement with the Company

Teilzeitvereinbarung Part-Time Agreement zwischen between COMPASS Pathfinder Limited COMPASS Pathfinder Limited - nachfolgend ?COMPASS? genannt - - hereinafter referred to as ?COMPASS? - und and Herrn Lars Wilde Mr.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression Largest randomised, controlled, double-blind psilocybin therapy study ever comple

EX-99.1 2 exhibit991-compass6xk.htm EX-99.1 Exhibit 99.1 COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psiloc

The Chief Financial Officer’s Settlement Agreement dated July 29, 2021 with the Company

ACTIVE/110759967.17 Dated 2021 COMPASS PATHFINDER LIMITED (1) and PIERS MORGAN (2) SETTLEMENT AGREEMENT 29 July ACTIVE/110759967.17 Table Of Contents 1. Interpretation ........................................................................................................................ 1 2. Arrangements on termination ..............................................................................

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

Exhibit 99.1 COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder London, UK ? 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1 (

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups Investigator-initiated study shows remission in major depression symptoms for 50% of p

Exhibit 99.1 Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK ? 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1 (

COMPASS Pathways is granted new US patent for crystalline psilocybin

Exhibit 99.1 COMPASS Pathways is granted new US patent for crystalline psilocybin London, UK ? 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). This is COMPASS?s

As filed with the Securities and Exchange Commission on October 8, 2021.

As filed with the Securities and Exchange Commission on October 8, 2021. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPASS Pathways plc (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant?s name into English) England and Wales N

Form of Subordinated Indenture (incorporated by reference to Exhibit 4.6 to the Registrant’s Registration Statement on Form F-3 (File No. 333-260145) filed with the Commission on October 8, 2021).

Exhibit 4.6 COMPASS PATHWAYS PLC FORM OF SUBORDINATED INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 6 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6

2021, by and between the Registrant and Cowen and Company, LLC.

Exhibit 1.2 COMPASS PATHWAYS PLC AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES SALES AGREEMENT October 8, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales with registered number 12696098 (the ?Company?), confirms its agreement (this ?Agreement?) with Co

Form of Senior Indenture (incorporated by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form F-3 (File No. 333-260145) filed with the Commission on October 8, 2021).

Exhibit 4.5 COMPASS PATHWAYS PLC FORM OF SENIOR INDENTURE Dated as of [ ], 20[ ] [ ] Trustee Table of Contents Page Article I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 6 Article II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Secti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-395

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1 (646) 905-3974 (Address of pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant’s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs London, UK ? 14 September 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances.

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

EX-99.3 3 q22021xpressreleasex20210.htm EX-99.3 COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021 London, UK – 11 August 2021 Highlights: •Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 •Partnership being developed with leading UK institutions to accel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of Aug 2021 Commission File Number: 001-39522 COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of Aug 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1 (646) 90

Lease Agreement by and between Fora Space Limited and the Company, dated July 9, 2021

Fora Space Limited (?Fora?) Residency Agreement Resident Name: Compass Pathfinder Limited Start Date: 01-Sep-2021 Initial Term (Months): 24 Location: Soho Office number(s): 2nd floor Principal contact details Name George Goldsmith Telephone 075 9563 6895 Title Mr.

COMPASS PATHFINDER LIMITED GUY GOODWIN

EX-99.2 3 compass-cmoservicecontract.htm EX-99.2 Dated 27 July 2021 COMPASS PATHFINDER LIMITED and GUY GOODWIN SERVICE AGREEMENT THIS AGREEMENT is entered into between the parties on 27 July 2021 PARTIES (1)COMPASS PATHFINDER LIMITED a company incorporated and registered in England and Wales with company number 10229259 and whose registered office is at 3rd Floor, 1 Ashley Road, Altrincham, Cheshi

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer COMPASS announces changes to its Executive Team

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer COMPASS announces changes to its Executive Team London, UK ? 29 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed eminent psychiatrist, Professor Guy Goodwin FMedSci, as Chief Medical Officer.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number: 001-39522 CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kingdom Tel: +1 (646) 905-3974 (Address of princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number: 001-39522 CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Ki

The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on June 16, 2021 for action to be taken.

Annual General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.

JOINT FILING AGREEMENT

EX-99.1 2 d46702dex991.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that theyare jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) (CUSIP Number) Rya

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Krausenstraße 9-10, 10117 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Number

Time Sensitive Materials

Time Sensitive Materials Depositary?s Notice of Annual General Meeting of COMPASS Pathways plc ADSs: American Depositary Shares.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kin

COMPASS PATHWAYS PLC (the “Company”) 3rd Floor 1 Ashley Road, Altrincham Cheshire WA14 2DT United Kingdom (Incorporated and registered in England and Wales under the Companies Act 2006 with registered number 12696098) THIS DOCUMENT IS IMPORTANT AND R

COMPASS PATHWAYS PLC (the ?Company?) 3rd Floor 1 Ashley Road, Altrincham Cheshire WA14 2DT United Kingdom (Incorporated and registered in England and Wales under the Companies Act 2006 with registered number 12696098) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

Time Sensitive Materials

Time Sensitive Materials Depositary?s Notice of Annual General Meeting of COMPASS Pathways plc ADSs: Restricted American Depositary Shares.

The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on June 16, 2021 for action to be taken.

Annual General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kin

COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021

COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021 London, UK ? 13 May 2021 Highlights: ?New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder ?Two further US patents granted ?Equity financing raises gross proceeds of $144 millio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Translation of registrant?s name into English) COMPASS Pathways plc 3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT United Kin

4,000,000 American Depositary Shares Representing 4,000,000 Ordinary Shares

Filed pursuant to Rule 424(b)(4) Registration No. 333-255552 Registration No. 333-255630 PROSPECTUS 4,000,000 American Depositary Shares Representing 4,000,000 Ordinary Shares We are offering 4,000,000 American Depositary Shares, or ADSs, of COMPASS Pathways plc. Each ADS represents one ordinary share, nominal value ?0.008 per ordinary share, of COMPASS Pathways plc. The ADSs may be evidenced by A

- F-1MEF

As filed with the Securities and Exchange Commission on April 29, 2021. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COMPASS Pathways plc (Exact name of registrant as specified in its charter) England and Wales 2834 Not applicable (State or other jurisdiction of incorporation

- F-1/A

Table of Contents As filed with the Securities and Exchange Commission on April 28, 2021.

[Signature page follows]

VIA EDGAR April 27, 2021 Office of Life Sciences Division of Corporation Finance U.

[Signature page follows]

April 27, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Power of Attorney

Table of Contents As filed with the Securities and Exchange Commission on April 27, 2021.

Form of Underwriting Agreement.

Exhibit 1.1 COMPASS Pathways plc [?] American Depositary Shares Representing [?] Ordinary Shares (Nominal Value ?0.008 Each) UNDERWRITING AGREEMENT [?], 2021 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. BERENBERG CAPITAL MARKETS LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street N

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Study concludes that psilocybin findings should be explored further in lar

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Study concludes that psilocybin findings should be explored further in larger studies London, UK ? 15 April 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 15, 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not applicable (State or other jurisdiction of incorporation or o

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 1, 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not applicable (State or other jurisdiction of incorporation or or

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors London, UK ? 1 April 2021 COMPASS Pathways plc (Nasdaq: CMPS) (?COMPASS?), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors.

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 23, 2021 Commission File Number: 001-39522 COMPASS PATHWAYS PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not applicable (State or other jurisdiction of incorporation or o

COMPASS Pathways granted two US patents

COMPASS Pathways granted two US patents London, UK – 23 March 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO).